Search results for "3a"

showing 10 items of 351 documents

Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of…

2021

Abstract Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). A key regulatory gene frequently mutated (∼75%) in PDAC is the TP53 tumor suppressor gene which controls the transcription of multiple genes involved in cell cycle progression, apoptosis, cancer progression and other growth regulatory processes. The mouse double minute 2 homolog (MDM2) gene product is a nuclear-localized E3 ubiquitin ligase and negatively regulates the TP53 protein which results in its proteasomal degradation. Various MDM2 inhibitors have been isolated and examined in clinical t…

Nutlin-3aCancer ResearchBerberineendocrine system diseasesTumor suppressor geneNAX compoundsApoptosisPiperazinesTargeted therapyGene productCell Line TumorPancreatic cancerGeneticsmedicineHumansTP53neoplasmsMolecular BiologyRegulator geneNAX compundsbiologyChemistryImidazolesPDACCancerProto-Oncogene Proteins c-mdm2PDCAmedicine.diseaseUbiquitin ligasePancreatic NeoplasmsCell culturebiology.proteinCancer researchNAX compoundMolecular MedicineMdm2Tumor Suppressor Protein p53Signal TransductionAdvances in Biological Regulation
researchProduct

Modulation of biotransformation and elimination systems by BM-21, an aqueous ethanolic extract from Thalassia testudinum, and thalassiolin B on human…

2012

Abstract BM-21 is an extract obtained from Thalassia testudinum marine plant with pharmacological properties. The effects of BM-21 and thalassiolin B (TB), its main component, on enzyme and transport proteins involved in drug metabolism and excretion in human cultured hepatocytes were evaluated. Cells were exposed for 48 h to sub-cytotoxic concentrations of BM-21 or TB. Effects on P450 isoforms revealed significant reductions of CYP1A2, 3A4 and 2D6 activities (up to 56%, 66% and 44% inhibition, respectively) after exposition to BM-21, no changes on CYP2A6 and 2C9 activities. TB produced a concentration-dependent reduction of all P450 activities. In addition, a decrease in total UGT and UGT2…

Nutrition and DieteticsbiologyCYP3A4Nutrition. Foods and food supplyThalassiolin BCYP1A2PolyphenolsMedicine (miscellaneous)Cytochrome P450Cytochrome P450P-glycoproteinPharmacologyExcretionBiotransformationIn vivobiology.proteinThalassia testudinumTX341-641UDP-glucuronosyltransferasesCYP2A6Drug metabolismFood ScienceJournal of Functional Foods
researchProduct

Metformintreatment Overcomes ATRA-Resistance in Acute Promyelocytic Leukemia and Increases FOXO3A Expression

2018

Abstract Introduction: FOXO3A is a transcription factor shown to be involved in all-trans retinoic acid (ATRA)-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia (APL). Its biological activity may be significantly enhanced upon metformin, raising the possibility that ATRA and Metformin may act synergistically; which could be useful to overcome ATRA resistance. Despite progress in APL treatment, approximately 10-15% of patients will relapse after treatment with ATRA and anthracyclines and frequently present with ATRA resistance. Relapsed patients respond well to arsenic trioxide (ATO) treatment, but the cost of ATO is a significant barrier in many countries. A…

OncologyAcute promyelocytic leukemiamedicine.medical_specialtyAcute leukemiaHematologySupervisory boardbusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryLeukemiaInternal medicineFOXO3A GenemedicinebusinessAfter treatmentLeukemic BlastsBlood
researchProduct

Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway gene…

2016

Oncologymedicine.medical_specialtysocs1030230 surgerymedicine.disease_causestat303 medical and health sciencesDNMT3A; SOCS1; STAT3; TP53; breast implant-associated anaplastic large-cell lymphoma; somatic mutations0302 clinical medicineInternal medicinemedicineAnaplastic lymphoma kinasebreast implant-associated anaplastic large-cell lymphomaSTAT3Anaplastic large-cell lymphomaMutationbiologySuppressor of cytokine signaling 1hematologyLarge cellJAK-STAT signaling pathwaybreast implantâ associated anaplastic large-cell lymphomatp53medicine.diseaseLymphomabreast implant-associated anaplastic large-cell lymphoma; dnmt3a; socs1; somatic mutations; stat3; tp53; hematology030220 oncology & carcinogenesisdnmt3aCancer researchbiology.proteinsomatic mutationsbreast implant–associated anaplastic large-cell lymphoma; DNMT3A; SOCS1; somatic mutations; STAT3; TP53; Hematology
researchProduct

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoin…

2021

Gastrointestinal stromal tumors (GISTs) represent 1% of all primary gastrointestinal tumors. Immune surveillance is often overcome by cancer cells due to the activation of immunoregulatory molecules such as programmed death protein (PD-1) and its ligand PD-L1, and butyrophilin sub-family 3A/CD277 receptors (BTN3A). Because several studies demonstrated that tumor PD-1 and PD-L1 expression may have a prominent prognostic function, this investigation aimed to discover if soluble forms of these molecules may be useful in predicting survival of metastatic GIST (mGIST) patients. Through specific ad hoc developed ELISA assays not yet available on the market, the circulating PD-1, PD-L1, BTN3A1, an…

PD-L10301 basic medicineCancer ResearchStromal cellSettore MED/06 - Oncologia MedicaArticle03 medical and health sciencesExon0302 clinical medicineImmune systemButyrophilinPD-L1PD-1Medicineprognostic biomarkerReceptorRC254-282butyrophilinsbiologyGiSTbusiness.industrycirculating immune checkpointsNeoplasms. Tumors. Oncology. Including cancer and carcinogensBTN3A1Antitumor immune response BTN3A1 Butyrophilins Circulating immune checkpoints GIST PD‐1 PD‐L1 Prognostic biomarkerantitumor immune response030104 developmental biologyOncology030220 oncology & carcinogenesisCancer cellCancer researchbiology.proteinbusinessGISTCancers
researchProduct

Cytochrome P450 reaction phenotyping and inhibition and induction studies of pinostrobin in human liver microsomes and hepatocytes

2017

Pinostrobin (PI, 5-hydroxy-7-methoxyflavanone) is a natural flavonoid known for its rich pharmacological activities. The objective of this study was to identify the human liver cytochrome P450 (CYP450) isoenzymes involved in the metabolism of PI. A single hydoxylated metabolite was obtained from PI after an incubation with pooled human liver microsomes (HLMs). The relative contributions of different CYP450s were evaluated using CYP450-selective inhibitors in HLMs and recombinant human CYP450 enzymes, and the results revealed the major involvement of CYP1A2, CYP2C9 and CYP2E1 in PI metabolism. We also evaluated the ability of PI to inhibit and induce human cytochrome P450 enzymes in vitro. H…

PharmacologyCYP2B6biologyCYP3A4ChemistryMetaboliteClinical BiochemistryCYP1A2Cytochrome P450General MedicineCYP2E1Pharmacology030226 pharmacology & pharmacyBiochemistryIsozymeAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBiochemistry030220 oncology & carcinogenesisDrug Discoverybiology.proteinMicrosomeMolecular BiologyBiomedical Chromatography
researchProduct

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

2014

Antonietta Caruso, Chiara Bellia, Alessia Pivetti, Luisa Agnello, Federica Bazza, Concetta Scazzone, Giulia Bivona, Bruna Lo Sasso, Marcello CiaccioDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, ItalyBackground: The aim of this study was to investigate the effect of two genetic polymorphisms in the coding regions (exon 3 and exon 4) of the EPHX1 gene, ie, 337T>C and 416A>G, respectively, on the metabolism of carbamazepine (CBZ) 10,11-epoxide (the active metabolite of CBZ) by evaluating the variation in serum CBZ 10,11-epoxide levels 4 hours after administration of the drug. Moreover, we reported the genotype frequencies of …

PharmacologyCYP3A4business.industryCarbamazepineEPHX1Pharmacologydrug metabolismGenotype frequency11-epoxidePharmacogenomics and Personalized MedicineIn vivoGenotypemedicineMolecular MedicineCBZ 10EPHX1 genebusinessActive metaboliteDrug metabolismCYP3A4*22medicine.drugOriginal ResearchPharmacogenomics and Personalized Medicine
researchProduct

Genetics of the variable expression of CYP3A in humans.

2004

CYP3A isozymes participate in the metabolism of 45-60% of currently used drugs and of a variety of other compounds such as steroid hormones, toxins, and carcinogens. The CYP3A expression status is a major determinant of drug efficacy and safety, and it may also affect an individual's predisposition to certain cancers. The inter- and intraindividual expression of CYP3A is variable because of a complex interplay between genetic and environmental factors. Markers predictive of the individual CYP3A activity could improve therapies with CYP3A substrates by personalised dose adjustments, but their development has been slower than for other drug-metabolizing enzymes. Here we summarize the recent p…

PharmacologyGeneticsRegulation of gene expressionPolymorphism GeneticCYP3A4GenomicsOxidoreductases N-DemethylatingBiologyIsozymeGene Expression Regulation EnzymologicVariable ExpressionPharmaceutical PreparationsOrgan SpecificityCytochrome P-450 CYP3ACytochrome P-450 CYP3AHumansPharmacology (medical)PharmacokineticsAryl Hydrocarbon HydroxylasesCYP3A5HormoneTherapeutic drug monitoring
researchProduct

CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy

2020

Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & methods: Brazilian kidney recipients were treated with TAC combined with everolimus (n = 178) or mycophenolate sodium (n = 97). The variants in CYP2C8, CYP2J2, CYP3A4, CYP3A5, POR, ABCB1, ABCC2, ABCG2, SLCO1B1 and SLCO2B1 were analyzed. Main results: CYP3A5*3/*3 genotype influenced increase in TAC concentration from week 1 to month 6 post-transplantation (p < 0.05). The living donor and CYP2C8*3 variant were associated with reduced risk for delayed graft function (OR = 0.07; 95% CI = 0.03–0.18 and OR = 0.45; 95% C…

PharmacologyKidneymedicine.medical_specialtyEverolimusbiologybusiness.industryGastroenterologyTacrolimusMycophenolic acidmedicine.anatomical_structurePharmacokineticsInternal medicineGeneticsmedicinebiology.proteinFARMACOCINÉTICAMolecular MedicineSLCO1B1CYP3A5businessCYP2C8medicine.drug
researchProduct

Transcriptional regulation and expression of CYP3A4 in hepatocytes.

2007

CYP3A4 is the most abundantly expressed drug-metabolizing P450 enzyme in human liver and contributes to the metabolism of a large number of drugs in use today. CYP3A4 is constitutively expressed in adult hepatocytes but it can also be transcriptionally induced by a variety of structurally diverse xenochemicals. CYP3A4 strongly contributes to the important variability in the therapeutic and toxic effects of drugs owing to the major role it plays in xenobiotic metabolism and the large intra- and inter-individual variability to which it is subjected. The functional examination of up to 13 kb of the CYP3A4 5'-flanking region has revealed that the regulation of this gene is a complex issue, with…

PharmacologyRegulation of gene expressionPregnane X receptorTranscription GeneticClinical BiochemistryDown-RegulationBiologyPharmacologyRegulatory Sequences Nucleic AcidGene Expression Regulation EnzymologicCell biologyDrug developmentNuclear receptorCytochrome P-450 Enzyme SystemLiverRegulatory sequenceTranscriptional regulationHepatocytesAnimalsCytochrome P-450 CYP3AHumansTranscription factorDrug metabolismCurrent drug metabolism
researchProduct